… factor receptor, gefitinib and erlotinib, have changed the treatment paradigm of advanced
non-… Many phase II or III studies have proven the efficacy of gefitinib or erlotinib as the first-line, …

… in the gefitinib and 17% in the erlotinib group discontinued therapy due to … treatment were,
respectively, 2.8 and 7.6 months in the erlotinib group, and 2.4 and 5.0 months in the gefitinib …

… We conducted a phase II study of erlotinib after failure of gefitinib treatment in patients with …
our study, of the 15 patients who benefited from gefitinib, two benefited from erlotinib treatment…

… The present study analyzed experiences in treating a large population of NSCLC patients
with gefitinib and erlotinib in order to reveal the trend on drug selection between the two TK …

… Treatment schedule … at a 1 : 1 ratio to receive oral erlotinib 150 mg or gefitinib 250 mg once
daily. Second- and further-line treatments were defined as second line in the present study. …

… A number of Lung Disease Site Group members, including two of the lead authors of this
systematic review, have been research investigators on clinical trials of gefitinib or erlotinib, …

… This study was the first to directly compare EGFR-TKIs treatment efficacy in … erlotinib- and
gefitinib-treated groups (11.7 vs. 14.5 months; P=0.507) in a retrospective case-control study of …

… entry, because we recognized that a significant proportion of patients included in this
study did not have EGFR activating mutation and may have had a shorter duration of …

… study showed that erlotinib and gefitinib had similar effectiveness but gefitinib had a better
safety profile compared to erlotinib… erlotinib and gefitinib for treating NSCLC in our study …

… The objective of this study was to compare the efficacy and toxicity of erlotinib, … We selected
all randomized studies of erlotinib or gefitinib as treatment of advanced or metastatic stage …